ACRS

Balthaser Kevin

Known title: Chief Financial OfficerCIK: 0001957554

Balthaser Kevin's purchase track record

Balthaser Kevin has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.

PurchaseStockAmount3 months6 months
9/6/2023ACRS$75K-86.5%-80.9%

Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 16, 2026

ACRS Not Highlighted in Recent Pre‑Market Moves. In the past week, pre‑market activity focused on large financial names and a list of 20 stocks, but Aclaris Therapeutics was not mentioned. The moves in big banks and other sectors could influence overall market sentiment, which may affect smaller biotech names like ACRS. No direct company news was reported, so the impact is limited at this time.

this person other insiders at ACRS

Transaction History

ACRS▲ Buy—
ACRS▼ Sell$2K
ACRS▲ Buy—
ACRS▼ Sell$22K
ACRS▲ Buy—
ACRS▼ Sell$17K
ACRS▲ Buy—
ACRS▼ Sell$13K
ACRS▲ Buy—
ACRS▼ Sell$7K
ACRS▲ Buy—
ACRS▼ Sell$60K
ACRS▲ Buy—
ACRS▲ Buy—
ACRS▼ Sell$1K
ACRS▲ Buy—
ACRS▼ Sell$14K
ACRS▲ Buy—
ACRS▼ Sell$13K
ACRS▲ Buy—
ACRS▼ Sell$6K
ACRS▲ Buy—
ACRS▼ Sell$76K
ACRS▲ Buy—
ACRS▼ Sell$337
ACRS▲ Buy—
ACRS▼ Sell$529
ACRS▲ Buy—
ACRS▼ Sell$388
ACRS▲ Buy—
ACRS▼ Sell$839
ACRS▲ Buy—
ACRS▼ Sell$3K
ACRS▲ Buy$75K
ACRS▲ Buy—
ACRS▼ Sell$2K
ACRS▼ Sell$11K
ACRS▼ Sell$12K
ACRS▲ Buy—
ACRS▲ Buy—
ACRS▲ Buy—
ACRS▲ Buy—

We use analytics to understand how market-wall is used. No personal data is sold.